share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/09 16:14
Moomoo AI 已提取核心訊息
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales will be made on the Nasdaq Capital Market and the company will pay a 3.0% commission to the Agent on the gross proceeds. There is no obligation for either party to proceed with the sale of any stock, and the number of shares sold, if any, as well as the prices and dates of sale, are not guaranteed. The agreement also includes indemnification provisions for the Agent. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold 1,075,405 shares for an aggregate offering price of $9.8 million. The termination was effective immediately, and no further sales will be made under the prior agreement. The new sales agreement and the termination of the old one were made pursuant to the company's effective registration statement and prospectus supplement filed with the SEC.
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales will be made on the Nasdaq Capital Market and the company will pay a 3.0% commission to the Agent on the gross proceeds. There is no obligation for either party to proceed with the sale of any stock, and the number of shares sold, if any, as well as the prices and dates of sale, are not guaranteed. The agreement also includes indemnification provisions for the Agent. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold 1,075,405 shares for an aggregate offering price of $9.8 million. The termination was effective immediately, and no further sales will be made under the prior agreement. The new sales agreement and the termination of the old one were made pursuant to the company's effective registration statement and prospectus supplement filed with the SEC.
2024年5月9日，Effector Therapeutics, Inc.宣佈與H.C. Wainwright & Co., LLC簽訂市場發行協議，允許該公司出售高達5000萬美元的普通股。銷售將在納斯達克資本市場上進行，公司將向代理人支付總收益的3.0％的佣金。任何一方都沒有義務繼續出售任何股票，也不能保證出售的股票數量（如果有）以及出售的價格和日期。該協議還包括對代理人的賠償條款。同時，Effector Therapeutics終止了先前與Cantor Fitzgerald & Co. 的協議，根據該協議，該公司出售了1,075,405股股票，總髮行價爲980萬美元。終止立即生效，根據先前的協議，將不再進行進一步的銷售。新的銷售協議和舊協議的終止是根據公司向美國證券交易委員會提交的有效註冊聲明和招股說明書補充文件簽訂的。
2024年5月9日，Effector Therapeutics, Inc.宣佈與H.C. Wainwright & Co., LLC簽訂市場發行協議，允許該公司出售高達5000萬美元的普通股。銷售將在納斯達克資本市場上進行，公司將向代理人支付總收益的3.0％的佣金。任何一方都沒有義務繼續出售任何股票，也不能保證出售的股票數量（如果有）以及出售的價格和日期。該協議還包括對代理人的賠償條款。同時，Effector Therapeutics終止了先前與Cantor Fitzgerald & Co. 的協議，根據該協議，該公司出售了1,075,405股股票，總髮行價爲980萬美元。終止立即生效，根據先前的協議，將不再進行進一步的銷售。新的銷售協議和舊協議的終止是根據公司向美國證券交易委員會提交的有效註冊聲明和招股說明書補充文件簽訂的。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息